Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29
European Journal of Cancer2013Vol. 50(4), pp. 706–712
Citations Over TimeTop 10% of 2013 papers
Scott A. Laurie, Benjamin Solomon, Lesley Seymour, Peter Ellis, Glenwood Goss, F. Shepherd, Michael Boyer, Andrew Arnold, Philip R. Clingan, Francis Laberge, David Fenton, Vera Hirsh, Mauro Zukin, Martin R. Stockler, C.W. Lee, E X Chen, Alexander Montenegro, Keyue Ding, Penelope A. Bradbury
Related Papers
- → Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer(2016)360 cited
- → Cell-cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy(2007)28 cited
- → S100P sensitizes ovarian cancer cells to carboplatin and paclitaxel in vitro(2008)19 cited
- Pharmacokinetics of paclitaxel and carboplatin in combination.(1995)
- Effects of CMNa combined with paclitaxel and carboplatin on elevated CA125 levels in post-operation advanced ovarian cancer patients(2008)